TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has signed a Letter of Intent with Cellin Technologies to commercialize its HG-CT-1 CAR-T cell therapy in Estonia for treating relapsed or refractory acute myeloid leukemia. This collaboration, utilizing Estonia’s hospital exemption pathway, represents the first potential near-term revenue opportunity for Hemogenyx, allowing the company to generate early revenue and expand real-world clinical data. Hemogenyx retains full ownership of intellectual property and will receive revenues from commercialization, while Cellin will provide local support. The partnership aims to position Estonia at the forefront of advanced cell therapy in Europe, demonstrating transformative outcomes for patients.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company is focused on developing new medicines and treatments for blood and autoimmune diseases, and is advancing several product candidates and platform technologies for novel product development.
Average Trading Volume: 122,216
Technical Sentiment Signal: Buy
Current Market Cap: £79.35M
For detailed information about HEMO stock, go to TipRanks’ Stock Analysis page.